Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Thank you for the most artful and masterful explanation of AVXL. You, JBEM, and Moneypennyoncs are
quite a combo for this board. Glad I found it.
Where are you reading this report from Justice and Equality? Can you provide a link?
True, of course. But you happen to be a person who has the ability to state information succinctly in a few words. Thanks again for your thoughtful reply.
Citrati: Thank you for the detailed reply. Much appreciated. DM
Now why did you have to bring up AT*X? You've been a stellar poster to date. BTW, if you had a stroke, you're telling me that you wouldn't take what AT*X had to offer? 18% of the population of stroke patients made a better recovery than not using at all.
T&L: I was referring solely to his sentence starting with, "I promise..."
I never said his reasoning is unsound. Thanks for the clarification though.
"I promise if we had full closed-loop control we would not be at .11-.12 cents."
M Duffy:
That statement is, of course, complete speculation on your part. We have discussed
at length SGLB's visibility or non-visibility and the public awareness of SGLB, and
we have discussed the non-visibility of SGLB's cooperation with GE and other large
corps. The truth is there are many factors that influence the pps.
Thank you!!!
The last link goes nowhere: try this one.
http://b6sigma.com
They announced they needed money last month. Nothing new.
This information has been on their website since buying the M290.
MP: I bought a couple of days ago. I am almost fed up with OTC stocks given their high manipulation and the ordeal of ONCS. All is hide and seek.
The Google Board has talked up AVXL and APHB but AVXL has a much lower MC and shares outstanding and science is very attractive.
Hope to see u here more often.
dawson
Moneypenny you're back!!! I promise I will never say anything bad to you again! Saw your reco on Google board and hopefully this board comes alive.
Thank you for the smart summary.
Oh vey back to you
Thank you for that information BUT it is referring to the March 10 announcement:
Total Offering Amount $13,000,000 USD
or Indefinite
Total Amount Sold $13,000,000 USD
Total Remaining to be Sold $0 USD
or Indefinite
Clarification of Response (if Necessary):
So I ask Lone Wolf again where did he see a "major investment fund," claim???
There was no news this morning - it was on March 10 and the funding has nothing to do with you call a "major investment fund." Check out what was written in the announcement:
AmpliPhi will use the proceeds from the fundraising to advance its three programs in methicillin-resistant staphylococcus aureus (MRSA), Pseudomonas aeruginosa infections in Cystic Fibrosis and Clostridium difficile. For its most advanced phage program, AmpliPhage-002 in MRSA, AmpliPhi intends to file an IND and commence Phase I clinical trials by year-end 2015. In its P. aeruginosa program (AmpliPhage-001) the Company expects to complete inhalation toxicology studies by the end of 2015. The Company's goal with respect to AmpliPhage-004 in C. difficile is to conclude pre-clinical efficacy studies during 2015.
Where did you get the idea of your claim? Please provide a link or don't spread disinformation.
You are NOT reading the news correctly which was announced on March 10. Come back over to the AP?B board and read my response.
Could you provide a link to this info?
Yea, you're the great and only wizard!
Great to hear from jjsmith!
Ur welcome, Lasers
That's okay. Always another place to find it if you can remember something about the title.
Despite what JBEM and Cam post, ONCS is still moving forward. This has been posted elsewhere, but WE NEED for you to vote on this site, which has named ONCS one of the best vaccine companies in 2015. Go to the bottom of the page and please vote for ONCS:
http://www.vaccinenation.org/2015/03/13/vie-awards-shortlist-announced-make/
what the name of the article - probably find it on PubMed
I'll let you know...
That's public knowledge and it has been for quite some time. All of Ziop's investors can't be irrational yet, they need you to tell them something different like "failed candidates." We're are discussing a biotech for pete's sake, which is analogous to a car having flat tires on occasion. The very nature of a biotech is trial and error, but this is what is missing in your argument: what happens if Ziop does create an advantage in its methodology? Like, their ORR goes up and a cancer patient doesn't have to stay over night in a hospital? This is the part that is missing from your presentation and the part that is gaining traction in the marketplace.
You are so adamant to be right, and it's really amazing that you don't know anything about this company. Really amazing!
I'll buy you a twinkie
I can answer that teacher.
one bearish opinion...with no freakin' facts except, uh-oh, the stock has gone up too fast, so it's gonna
come down. love the bear outfit and the anonymous names especially when writing for SA.
great find, Wait!
What does that mean? Grab more... Wish you had another 10K layin' around?
What about ADXS and MDGN?
And with all of this innovation, the PPSb continues to decline. Unbelievable. Can this be the work
of shorts???
Why does it have to be a wager? If you know there has been further dilution, show it.
Arcam is in Wikipedia for EBM:
http://en.wikipedia.org/wiki/Electron_beam_melting
Is this old news:
Company checkpoints
By Stephen Parmley, Senior Writer
Published on Thursday, January 29, 2015
The spate of biotechs announcing new targets, combinations or milestones in the PD-1space in the last two months suggests pharmas may not have to wait long to add second-generation therapies to their pipelines of checkpoint inhibitors. While AnaptysBio Inc. and cCAM have preclinical targets that could complement PD-1 inhibition, OncoSec Medical Inc. is about to enter the clinic with a combination that uses PD-1 suppression to potentiate the immune activation of IL-12.
The push for new compounds is driven by the fact that many patients don't respond to PD-1 therapies because their tumors have either low or no expression of the receptor's ligand, PD-L1. By acting through complementary pathways, upregulating the expression of PD-L1 or increasing the ability of antigen-presenting cells to trigger immune pathways, the next generation of compounds is designed to potentiate the tumor-killing effect of PD-1 inhibitors (See Cover Story).
Nice to see you back talking about ONCS.
Thanks for the explanation.
I'm not sure I understand. This is a recent article and yes electroporation has been around since the 1930's; however in this article it states effectiveness:
The effects of this process have been confirmed in countless small trials
What else is needed?